Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04454996
Other study ID # ZZ13-ZD-02
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date June 25, 2020
Est. completion date March 30, 2022

Study information

Verified date June 2020
Source Xiyuan Hospital of China Academy of Chinese Medical Sciences
Contact lin lv
Phone 18811782728
Email lushangshitou@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To clarify the changes of intestinal flora - gut - brain axis in FGIDs patients represented by NERD disharmony of liver and stomach and IBS-D disharmony of liver and spleen, and confirm that the imbalance between intestinal flora and host co-metabolism is the key to the pathogenesis of functional gastrointestinal disease. To reveal the common mechanism of regulating liver and spleen (stomach) in treating FGIDs dynamic disorder and visceral hypersensitivity by regulating intestinal flora - intestine - brain axis disorder.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date March 30, 2022
Est. primary completion date September 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Healthy volunteers with no abnormal clinical manifestations;

2. Meet the diagnostic criteria of NERD syndrome of disharmony of liver and stomach and IBS-D syndrome of liver depression and spleen deficiency.

3. Aged between 18 and 70.

4. Did not take antibiotics, steroids or other hormones, Chinese herbal preparations (including oral and intravenous administration), microecological preparations or probiotics such as yogurt for nearly a week;

5. Subjects are informed and sign informed consent voluntarily;

6. Have certain reading ability.

Exclusion Criteria:

1. Patients with severe lesions of the heart, liver, kidney and other major organs, hematopoietic system, nervous system or mental diseases;

2. Complicated with other organic diseases of the digestive system (such as peptic ulcer), or systemic diseases that affect the dynamics of the digestive tract (such as hyperthyroidism and diabetes);

3. Ongoing or ongoing use of drugs that may affect gastrointestinal function (antidiarrals, antidepressants, anti-anxiety drugs, intestinal microflora regulation drugs, antibiotics, etc.);

4. Those with a history of allergy to related drugs or severe food allergy used in the research.

5. The body is colonized with metal medical devices. (6) Having a pregnancy plan within three months.

-

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
tong-jiang granules
This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.
Chang 'an II Recipe
This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
The placebo of tong-jiang granules
This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
The placebo of Chang 'an II Recipe
This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.

Locations

Country Name City State
China Xiyuan Hospital of China Academy of Chinese Medical Science Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Xiyuan Hospital of China Academy of Chinese Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in 7 point Likert scale scores The score of patients on the degree of remission of gastroesophageal reflux disease symptoms (acid reflux and heartburn) (1 point for obvious improvement of symptoms, 2 points for improvement of symptoms, 3 points for slight improvement of symptoms, 4 points for no change, 5 points for slight aggravation of symptoms, 6 points for aggravation of symptoms, and 7 points for obvious aggravation of symptoms) Baseline, 2 weeks and 4 weeks during treatment period,4 weeks , 8 weeks , 12 weeks and 16 weeks during follow-up period
Primary Changes in irritable bowel syndrome symptom severity scale scores Irritable bowel syndrome symptom severity scale scores were assessed before and after treatment and during follow-up. The scoring standard is the same as the international standard. Baseline, 2 weeks and 4 weeks during treatment period,4 weeks , 8 weeks , 12 weeks and 16 weeks during follow-up period